You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.

Reassurance, Refunds & Replacements

If your product does not perform as described on this datasheet, we will refund or replace your product...

Read our guarantee »
 

Anti-VEGF antibody [VG-1] (ab1316)

CodeSizePriceAbpointsAvailability
    
 
  • -
  •   
  •   
  •   
  •  
  •   
  •   
Updating...

Overview

Product name

Anti-VEGF antibody [VG-1]
See all VEGF products (26) ...

Description

Mouse monoclonal [VG-1] to VEGF

Specificity

Detects the 121, 165 and 189 VEGF isoforms in routinely fixed specimens.

Tested applications

ICC/IF, IP, WB, ELISA, ICC, IHC-P, IHC-Frmore details

Cross reactivity

Reacts with

Mouse, Rat, Dog, Human

Does not react with

Cow

Immunogen

BALB/C mice were injected with a recombinant VEGF protein.

Positive control

Corpus luteum, VEGF165 recombinant protein, astrocytoma or hemoangiosarcoma

Properties

Form

Liquid

Storage instructions

Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.

Storage buffer

Preservative: None
Constituents: PBS

Concentration

Concentration information loading...

Purity

IgG fraction

Clonality

Monoclonal

Clone number

VG-1

Isotype

IgG1

Light chain type

kappa

  • Immunocytochemistry/ Immunofluorescence - VEGF antibody [VG1] (ab1316)Immunocytochemistry/ Immunofluorescence - VEGF antibody [VG1] (ab1316) image (enlarge)

  • Western blot - VEGF antibody [VG-1] (ab1316)Western blot - VEGF antibody [VG-1] (ab1316) image (enlarge)

  • Immunocytochemistry/ Immunofluorescence - VEGF antibody [VG-1] (ab1316)Immunocytochemistry/ Immunofluorescence - VEGF antibody [VG-1] (ab1316) image (enlarge)

Applications

Show applications key

Our Abpromise guarantee covers the use of ab1316 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Target

Function

Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth.

Tissue specificity

Isoform VEGF189, isoform VEGF165 and isoform VEGF121 are widely expressed. Isoform VEGF206 and isoform VEGF145 are not widely expressed.

Involvement in disease

Defects in VEGFA are a cause of susceptibility to microvascular complications of diabetes type 1 (MVCD1) [MIM:603933]. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.

Sequence similarities

Belongs to the PDGF/VEGF growth factor family.

Cellular localization

Secreted. VEGF121 is acidic and freely secreted. VEGF165 is more basic, has heparin-binding properties and, although a signicant proportion remains cell-associated, most is freely secreted. VEGF189 is very basic, it is cell-associated after secretion and is bound avidly by heparin and the extracellular matrix, although it may be released as a soluble form by heparin, heparinase or plasmin.

Target information above from: UniProt accessionP15692 The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010).

Information by UniProt

Alternative names

  • MGC70609 antibody
  • Vascular endothelial growth factor A antibody
  • Vascular Endothelial Growth Factor antibody
  • Vascular Permeability Factor antibody
  • VEGF-A antibody
  • VEGFA antibody
  • VEGFA_HUMAN antibody
  • VPF antibody
see all

Anti-VEGF antibody [VG-1] images:

  Immunocytochemistry/ Immunofluorescence - VEGF antibody [VG1] (ab1316)

Immunocytochemistry/ Immunofluorescence - VEGF antibody [VG1] (ab1316)

ab1316 at 10µg/ml staining human retinal pigment epithelial cells. The antibody was incubated with the cells for 6 hours and then detected with Alexa-Fluor ® 568 goat anti-mouse (IgG) antibody.

This image is courtesy of an Abreview submitted on 16 November 2005.

See Abreview

  Western blot - VEGF antibody [VG-1] (ab1316)

Western blot - VEGF antibody [VG-1] (ab1316)

All lanes : Anti-VEGF antibody [VG-1] (ab1316) at 10 µg/ml

Lane 1 : Jurkat (Human T cell lymphoblast-like cell line) Whole Cell Lysate
Lane 2 : A431 (Human epithelial carcinoma cell line) Whole Cell Lysate
Lane 3 : HepG2 (Human hepatocellular liver carcinoma cell line) Whole Cell Lysate

Lysates/proteins at 20 µg per lane.

Secondary
Goat polyclonal to Mouse IgG - H&L - Pre-Adsorbed (HRP) (ab65485) at 1/3000 dilution

Predicted band size : 24, 45 kDa
Observed band size : 43 kDa (why is the actual band size different from the predicted?)
Additional bands at : 125 kDa,52 kDa. We are unsure as to the identity of these extra bands.

  Immunocytochemistry/ Immunofluorescence - VEGF antibody [VG-1] (ab1316)

Immunocytochemistry/ Immunofluorescence - VEGF antibody [VG-1] (ab1316)

ICC/IF image of ab1316 stained HeLa cells. The cells were 100% methanol fixed (5 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab1316, 10µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-mouse IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM. This antibody also gave a positive result in 100% methanol fixed (5 min) Hek293, HepG2 and MCF7 cells at 10µg/ml, and in 4% PFA fixed (10 min) HeLa, Hek293, HepG2 and MCF7 cells at 10µg/ml.

  Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - VEGF antibody [VG-1] (ab1316)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - VEGF antibody [VG-1] (ab1316)

ab1316 staining VEGF in Human MDA-MD-231 cells injected into the mouse mammary fat pad by Immunohistochemistry (IHC-P - formaldehyde-fixed, paraffin-embedded sections). Tissue was fixed with paraformaldehyde, permeabilized with Tween in PBS and blocked with 1.5% serum for 1 hour at 25°C; antigen retrieval was by heat mediation in citrate buffer. Tissue samples were incubated with primary antibody (1/200 in PBST +1% BSA) for 16 hours at 4°C. A biotin-conjugated Goat anti-mouse IgG polyclonal (1/200) was used as the secondary antibody. Tissue was counterstained with Hematoxylin (1/10) for 30 seconds at room temperature and rinsed with water.

This image is courtesy of an anonymous Abreview

See Abreview

  Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VEGF antibody [VG-1] (ab1316)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VEGF antibody [VG-1] (ab1316)

IHC image of ab1316 staining in human heart formalin fixed paraffin embedded tissue section, performed on a Leica BondTM system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab1316, 5µg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.

For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.

References for Anti-VEGF antibody [VG-1] (ab1316)

This product has been referenced in:

  • Kushiyama Tet al. Effects of liposome-encapsulated clodronate on chlorhexidine gluconate-induced peritoneal fibrosis in rats. Nephrol Dial Transplant : (2011).Read more (PubMed: 21362737) »
  • Zheng Yet al. Microstructured templates for directed growth and vascularization of soft tissue in vivo. Biomaterials 32:5391-401 (2011). IHC-P; Mouse.Read more (PubMed: 21549426) »

See all 16 publications for this product

Publishing research using ab1316? Please let us know so that we can cite the reference in this datasheet

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"